Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients
Researchers used blood platelets and bone marrow cells to deliver potentially curative
to mouse models of the human genetic disorder Hurler syndrome – an often fatal condition that causes organ damage and other medical complications.
Scientists from Cincinnati Children’s Hospital Medical Center and the National Institute of Neurological Disorders and Stroke (NINDS) report their unique strategy for treating the disease the week of Feb. 3-7 in Proceedings of the National Academy of Sciences (PNAS).
Researchers were able to genetically insert into the cells a gene that produces a critical lysosomal enzyme (called IDUA) and then inject the engineered cells into mice to treat the disorder. Follow up tests showed the treatment resulted in a complete metabolic correction of the disease, according to the authors.
“Our findings demonstrate a unique and somewhat surprising delivery pathway for lysosomal enzymes,” said Dao Pan, PhD, corresponding author and researcher in the Division of Experimental Hematology and Cancer Biology at Cincinnati Children’s. “We show proof of concept that platelets and megakaryocytes are capable of generating and storing fully functional lysosomal enzymes, which can lead to their targeted and efficient delivery to vital tissues where they are needed.”
The mice tested in the study modeled human Hurler syndrome, a subset of disease known as mucopolysaccharidosis type I (MPS I), one of the most common types of lysosomal storage diseases. MPS I is a lysosomal storage disease in which people do not make an enzyme called lysosomal alpha-L-iduronidase (IDUA).
IDUA helps break down sugar molecules found throughout the body, often in mucus and fluids around joints, according to the National Library of Medicine/National Institutes of Health. Without IDUA, sugar molecules build up and cause organ damage. Depending on severity, the syndrome can also cause deafness, abnormal bone growth, heart valve problems, joint disease, intellectual disabilities and death.
Enzyme replacement therapy can be used to treat the disease, but it is only temporary and not curative. Bone marrow transplant using hematopoietic stem cells also has been tested on some patients with mixed results. The transplant procedure can carry severe risks and does not always work.
Pan and her colleagues – including Roscoe O. Brady, MD, a researcher at NINDS – report that using platelets and megakaryocytes for gene therapy is effective and could reduce the risk of activating cancer-causing oncogenes in hematopoietic stem cells.
The authors said tests showed that human megakaryocytic cells were capable of overexpressing IDUA, revealing their capacity for potential therapeutic benefit. While engineering megakaryocytes and platelets for infusion into their mouse models of Hurler, the scientists report they were able to release IDUA directly into amply sized extracellular spaces or inside micro-particles as the cells matured or activated. The cells were able to produce and package large amounts of functional IDUA and retained the capacity to cross-correct patient cells.
After infusing mouse models of Hurler with the genetically modified cells, researchers said this led to long-term normalization of IDUA levels in the animal’s blood with versatile delivery routes and on-target preferential distribution to the liver and spleen. The treatment led to a complete metabolic correction of MPS I in most peripheral organs of the mice.
Researchers cautioned that study results involving laboratory mouse models do not always translate into clinical treatment of human patients, and that additional research is needed for this prospective therapy.
The Latest on: Hurler syndrome
via Google News
The Latest on: Hurler syndrome
- JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japanon March 23, 2021 at 4:49 am
Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler syndrome, Hurler-Scheie, and Scheie syndrome), MPS II (Hunter syndrome), Pompe ...
- JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japanon March 23, 2021 at 4:33 am
Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler syndrome, Hurler-Scheie, and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease ...
- ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS Ion March 17, 2021 at 5:00 pm
MPS I affects approximately 3,000-4,000 patients worldwide. The most severe form of MPS I, Hurler syndrome affects several organs, including the brain, resulting in somatic and neurological ...
- Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishmentson March 2, 2021 at 12:57 pm
in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021 BOSTON and LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global ...
- Orchard Therapeutics plc (ORTX)on February 24, 2021 at 4:00 pm
Interactive chart for Orchard Therapeutics plc (ORTX) – analyse all of the data with a huge range of indicators.
- Jesus Gives MPS Families Victory in Deathon February 24, 2021 at 4:00 pm
Just shy of his first birthday, Loren was diagnosed with a rare terminal disease - Mucopolysacchridosis (MPS) Type I-H or Hurler Syndrome. Hurler Syndrome is one of three manifestations of MPS ...
via Bing News